Paclitaxel Timeline:
- Meta-analysis finds a higher risk of death in the long term when paclitaxel-coated devices are used in the leg
- Without additional long-term and patient-level data, Katsanos et al’s conclusion is premature
- SWEDEPAD 1 and SWEDEPAD 2 trials halt inclusion after Katsanos et al’s meta-analysis on paclitaxel-coated devices and interim safety analysis
- Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical study
- US FDA evaluating paclitaxel data, recommend patient surveillance
- Patient-level analysis at LINC from Medtronic, Cook Medical, and Philips reports no link between paclitaxel dose and mortality
- BASIL-3 trial pauses for review of paclitaxel meta-analysis data
- Society for Cardiovascular Angiography and Interventions supports continued use of paclitaxel devices
- ISET Paclitaxel Town Hall: Vast majority of attendees will not change their practice following recent Katsanos meta-analysis
- Medtronic and Cook Medical issue corrections to published data regarding the safety of their paclitaxel-covered devices
- Vascular Leaders Forum discussions seek consensus on paclitaxel
- CRT panellists vote overwhelmingly for there being a mortality signal
- CX aims to give the last word
